MX2022013490A - Composicion de la vacuna de poliepitopo contra citomegalovirus humano. - Google Patents
Composicion de la vacuna de poliepitopo contra citomegalovirus humano.Info
- Publication number
- MX2022013490A MX2022013490A MX2022013490A MX2022013490A MX2022013490A MX 2022013490 A MX2022013490 A MX 2022013490A MX 2022013490 A MX2022013490 A MX 2022013490A MX 2022013490 A MX2022013490 A MX 2022013490A MX 2022013490 A MX2022013490 A MX 2022013490A
- Authority
- MX
- Mexico
- Prior art keywords
- human cytomegalovirus
- vaccine composition
- polyepitope vaccine
- polyepitope
- disclosed
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901334A AU2020901334A0 (en) | 2020-04-28 | Pharmaceutical composition | |
| PCT/AU2021/050385 WO2021217206A1 (en) | 2020-04-28 | 2021-04-28 | Human cytomegalovirus polyepitope vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013490A true MX2022013490A (es) | 2023-01-05 |
Family
ID=78373118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013490A MX2022013490A (es) | 2020-04-28 | 2021-04-28 | Composicion de la vacuna de poliepitopo contra citomegalovirus humano. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230173061A1 (https=) |
| EP (1) | EP4143208A4 (https=) |
| JP (1) | JP2023526766A (https=) |
| KR (1) | KR20230005899A (https=) |
| CN (1) | CN117202929A (https=) |
| AU (1) | AU2021263337A1 (https=) |
| BR (1) | BR112022021769A2 (https=) |
| CA (1) | CA3177020A1 (https=) |
| IL (1) | IL297736A (https=) |
| MX (1) | MX2022013490A (https=) |
| WO (1) | WO2021217206A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2889064A1 (en) * | 2012-10-19 | 2014-04-24 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
| JP2019520332A (ja) * | 2016-05-23 | 2019-07-18 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Ｃｍｖエピトープ |
-
2021
- 2021-04-28 WO PCT/AU2021/050385 patent/WO2021217206A1/en not_active Ceased
- 2021-04-28 US US17/921,945 patent/US20230173061A1/en active Pending
- 2021-04-28 AU AU2021263337A patent/AU2021263337A1/en active Pending
- 2021-04-28 JP JP2022564217A patent/JP2023526766A/ja active Pending
- 2021-04-28 IL IL297736A patent/IL297736A/en unknown
- 2021-04-28 KR KR1020227040909A patent/KR20230005899A/ko active Pending
- 2021-04-28 EP EP21796930.2A patent/EP4143208A4/en active Pending
- 2021-04-28 MX MX2022013490A patent/MX2022013490A/es unknown
- 2021-04-28 BR BR112022021769A patent/BR112022021769A2/pt unknown
- 2021-04-28 CA CA3177020A patent/CA3177020A1/en active Pending
- 2021-04-28 CN CN202180045562.6A patent/CN117202929A/zh not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20230173061A1 (en) | 2023-06-08 |
| JP2023526766A (ja) | 2023-06-23 |
| CN117202929A (zh) | 2023-12-08 |
| WO2021217206A1 (en) | 2021-11-04 |
| EP4143208A4 (en) | 2024-06-05 |
| IL297736A (en) | 2022-12-01 |
| AU2021263337A1 (en) | 2022-11-24 |
| KR20230005899A (ko) | 2023-01-10 |
| EP4143208A1 (en) | 2023-03-08 |
| BR112022021769A2 (pt) | 2022-12-13 |
| CA3177020A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501366A1 (en) | Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them | |
| WO2020063370A3 (zh) | 免疫组合物及其制备方法与应用 | |
| WO2020193688A3 (en) | Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof | |
| PH12015502790A1 (en) | Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof | |
| ZA202003770B (en) | Mhc class i associated peptides for prevention and treatment of multiple flavi virus | |
| EP4458975A3 (en) | Hbv vaccines and methods treating hbv | |
| HUP9902438A2 (hu) | Parapoxvírus vektorok | |
| MY191322A (en) | Recombinant vectors expressing antigens of avian influenza virus and uses thereof | |
| TW201612316A (en) | Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition | |
| NZ730802A (en) | Therapeutic hpv16 vaccines | |
| NZ745327A (en) | Whole-cell cancer vaccines and methods for selection thereof | |
| MX2022002823A (es) | Composiciones inmunoterapeuticas. | |
| PH12021552648A1 (en) | Csfv subunit vaccine | |
| PH12022550541A1 (en) | Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l | |
| PH12021551816A1 (en) | Inactivated apxia, apxiia and apxiiia toxins | |
| MY202196A (en) | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses | |
| MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
| MX2022007398A (es) | Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas. | |
| WO2020074908A3 (en) | Treatment and prevention of malaria based on the antigen pfrh5 and antibodies against the same | |
| WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
| MX2017016273A (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante. | |
| MX2022013490A (es) | Composicion de la vacuna de poliepitopo contra citomegalovirus humano. | |
| WO2022104002A9 (en) | Sars-cov-2 immunodominant peptide constructs and uses thereof | |
| MX2020009720A (es) | Virus recombinante capaz de expresar de manera estable proteinas objetivo. | |
| Heit et al. | Circumvention of regulatory CD4+ T cell activity during cross‐priming strongly enhances T cell‐mediated immunity |